CLL is usually a slow-growing disease and can remain stable for years without the need for any treatment. While the appearance of swollen lymph nodes could mean that cancer has started to progress, ...

Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma After developing model parameters from the CLL8/10/11 and MURANO ...

Two patients with chronic lymphocytic leukemia (CLL) can face very different futures. One may live for decades without needing treatment, while another may develop rapidly progressing disease. In a ...

A key question you’ll likely have after chronic lymphocytic leukemia (CLL) treatment is how well it worked. At that point, your care team may mention “remission,” which means there’s no sign of cancer ...

Discover expert-backed insights on fitness, nutrition, sleep, and healthy aging to help you feel your best—every day, at every stage of life. Discover expert-backed insights on fitness, nutrition, ...

Utilization of novel Bruton tyrosine kinase inhibitors (BTKi) has become common for treating CLL/SLL patients, yet limited evidence exists on the clinical characteristics and outcomes following BTKi ...

“Bruin CLL-322 was an ambitious trial, building on an effective regimen, and these results outperformed our expectations,” Jacob Van Naarden, president of Lilly Oncology, said in an April 13 release. ...

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

Acalabrutinib/venetoclax may offer less toxicity compared with other therapies in chronic lymphocytic leukemia, said Nicole Lamanna, MD. Lamanna, an associate ...

Jaypirca significantly reduced the risk of progression or death by 80% compared with the traditional regimen of bendamustine and rituximab in patients with previously untreated chronic lymphocytic ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...